Streetbeat News

Stock Prices

GAN

GAN (NASDAQ:GAN) reported Q4 earnings with a significant miss on estimated earnings by -40.0%, posting an EPS of $-0.21 against an estimate of $-0.15. Revenue also saw a decrease of $6.23 million from the same period last year. This follows a pattern of fluctuating performance in previous quarters, with the last quarter showing a beat on EPS estimates but no subsequent increase in share price.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 1:35 pm

TRDA

Entrada Therapeutics (NASDAQ:TRDA) reported Q4 earnings with a significant miss on estimated earnings by -71.0%, posting an EPS of $-0.29 against an estimate of $-0.17. However, revenue saw an increase of $41.85 million from the same period last year. Despite beating EPS estimates last quarter, the share price dropped by 1.0% the following day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 1:35 pm

HPH

Puyi Inc. has officially changed its name to Highest Performances Holdings Inc., along with its ticker symbol from 'PUYI' to 'HPH'. The change follows shareholder approval of several resolutions, including amending the company's authorized share capital and exempting the company from holding an annual general meeting. The new structure includes 1,950,000,000 Ordinary Shares and 50,000,000 Preference Shares, with each Preference Share granting twenty votes.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 1:34 pm

SOS

Shares of SOS were halted due to a circuit breaker trigger after the stock plummeted by 20.7%.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 1:32 pm

DG

Dollar General Corp (NYSE:DG) is set to report its Q4 earnings on March 14, with Wall Street expecting $1.75 EPS and $9.78 billion in revenues. The stock has seen a significant recovery, up 55% since Oct. 2, 2023, and about 19% in 2024 so far. A Golden Cross is about to be triggered, indicating a bullish trend reversal. Analyst consensus rates the stock as Neutral with a price target of $134.07, though recent reviews suggest a target of $155-$158. The stock closed at $161.22 on March 12.

Portfolio Pulse from Surbhi Jain

March 13, 2024 | 1:30 pm

CUE

Cue Biopharma's stock price increased following Jefferies' initiation of coverage with a Buy rating and a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 1:29 pm

AGRX

Agile Therapeutics' stock price increased following the announcement that the company has fully paid off its debt facility with Perceptive Advisors.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 1:29 pm

WOW

WideOpenWest (WOW) shares dropped following the announcement of disappointing Q4 financial results and future guidance.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 1:27 pm

BNED

Barnes & Noble Education (BNED) shares have increased following the announcement of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 1:26 pm

DHI

GOOG

PFE

PGR

On CNBC's 'Halftime Report Final Trades,' experts highlighted their picks: Pfizer (PFE) for its promising Phase 3 study results, Alphabet (GOOG/GOOGL) despite a recent setback with its Pixel 8 smartphone, Progressive (PGR) for its solid earnings and growth prospects, and D.R. Horton (DHI) for its attractive valuation. Notably, Alphabet's Google faced a hiccup with its Pixel 8 smartphone lacking the Gemini Nano AI feature, and Progressive received an upgrade from Morgan Stanley.

Portfolio Pulse from Avi Kapoor

March 13, 2024 | 1:25 pm